Renoprotective Effect of Telmisartan in Patients with Chronic Kidney Disease
- 1 January 2008
- journal article
- research article
- Published by Taylor & Francis Ltd in Clinical and Experimental Hypertension
- Vol. 30 (7), 662-672
- https://doi.org/10.1080/10641960802443373
Abstract
Although the activation of the renin-angiotensin system has a major role in the development of chronic renal failure, little is known about the effect of angiotensin receptor blockers on tubulointerstitial injury. To evaluate the renoprotective effect of telmisartan, we measured urinary protein excretion, urinary liver-type fatty acid binding protein (L-FABP) excretion, and urinary collagen IV in 30 hypertensive patients with chronic kidney disease (CKD). These patients were randomly assigned to receive 40 mg/day (n = 15) or 80 mg/day (n = 15) of telmisartan before the initiation of treatment and 6 and 12 months after treatment. Both doses of telmisartan reduced systolic and diastolic blood pressure after 6 (p < 0.001) and 12 (p < 0.001) months compared with baseline levels. Blood pressure reduction rate were similar between both doses. Urinary protein, urinary L-FABP excretion, and urinary collagen IV levels declined significantly 6 (p < 0.001) and 12 (p < 0.001) months after telmisartan treatment in both doses. The reduction rate in parameters was more pronounced in patients receiving 80 mg/day compared with those taking 40 mg/day telmisartan at 12 months (p < 0.001). Telmisartan reduces proteinuria, urinary L-FABP excretion, and urinary collagen IV levels in hypertensive CKD patients.Keywords
This publication has 34 references indexed in Scilit:
- Comparison of Renal and Vascular Protective Effects between Telmisartan and Amlodipine in Hypertensive Patients with Chronic Kidney Disease with Mild Renal InsufficiencyHypertension Research, 2008
- Azelnidipine Reduces Urinary Protein Excretion and Urinary Liver-Type Fatty Acid Binding Protein in Patients with Hypertensive Chronic Kidney DiseaseThe American Journal of the Medical Sciences, 2007
- Risk of Developing Low Glomerular Filtration Rate or Elevated Serum Creatinine in a Screened Cohort in Okinawa, JapanHypertension Research, 2007
- Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor γCardiovascular Research, 2006
- New Treatment Strategies for Patients with Hypertension and Insulin ResistanceAmerican Journal Of Medicine, 2006
- Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney diseaseMolecular and Cellular Biochemistry, 2006
- TelmisartanDrugs, 2006
- Renoprotective Properties of Angiotensin Receptor Blockers beyond Blood Pressure LoweringJournal of the American Society of Nephrology, 2005
- Relationship between levels of urinary type IV collagen and renal injuries in patients with IgA nephropathyJournal of Clinical Laboratory Analysis, 2004
- Obstructive nephropathy and renal fibrosisAmerican Journal of Physiology-Renal Physiology, 2002